Javitt transcript seems to suggest that NeuroRx partnership only includes inhaled version of aviptadil.
Javitt is talking about manufacturing and he emphasizes the NeuroRx manufacturing of the inhaled version but he doesn't say anything about NeuroRx and the intravenous version.
The NeuroRx press release doesn't say anything about NeuroRx manufacturing of the intravenous version.
It would seem certain to me that NeuroRx deal includes intravenous but I can't find any explicit confirmation of that fact.
The Javitts interview does explain that intravenous aviptadil is currently being manufactured by compounding pharmacies.
A compounding pharmacy is a regular pharmacy except that they can also make their own mixtures of drugs. So apparently these compounding pharmacies can make the intravenous version of aviptadil.
So the Javitt interview comments that intravenous aviptadil is currently manufactured by compounding pharamacies certainly show a flaw in the intravenous aviptadil manufacturing.
Probably they should explicitly say that the NeuroRx partnership will inlcude manufacturing of intravenous product so compounding pharmacies are not doing it.
Or maybe the compounding pharmacies can make as much intravenous aviptadil as is needed for covid?
Anyone have any idea about the intravenous aviptadil manufacturing?
Javitt is talking about manufacturing and he emphasizes the NeuroRx manufacturing of the inhaled version but he doesn't say anything about NeuroRx and the intravenous version.
The NeuroRx press release doesn't say anything about NeuroRx manufacturing of the intravenous version.
It would seem certain to me that NeuroRx deal includes intravenous but I can't find any explicit confirmation of that fact.
The Javitts interview does explain that intravenous aviptadil is currently being manufactured by compounding pharmacies.
A compounding pharmacy is a regular pharmacy except that they can also make their own mixtures of drugs. So apparently these compounding pharmacies can make the intravenous version of aviptadil.
So the Javitt interview comments that intravenous aviptadil is currently manufactured by compounding pharamacies certainly show a flaw in the intravenous aviptadil manufacturing.
Probably they should explicitly say that the NeuroRx partnership will inlcude manufacturing of intravenous product so compounding pharmacies are not doing it.
Or maybe the compounding pharmacies can make as much intravenous aviptadil as is needed for covid?
Anyone have any idea about the intravenous aviptadil manufacturing?
